Pfizer Inc.: Market Signals Diverge After AstraZenica Bid Rejected (Capital Markets Research) - Moody's Capital Markets Research

Pfizer Inc.: Market Signals Diverge After AstraZenica Bid Rejected (Capital Markets Research)

Pfizer Inc.: Market Signals Diverge After AstraZenica Bid Rejected (Capital Markets Research) - Moody's Capital Markets Research
Pfizer Inc.: Market Signals Diverge After AstraZenica Bid Rejected (Capital Markets Research)
Published May 20, 2014
6 pages — Published May 20, 2014
Price US$ 200.00  |  Buy this Report Now

About This Report

  
Brief Excerpt:

...In the first full trading day after the May 19 announcement that AstraZeneca declined Pfizer s takeover offer, the CDS-implied rating for Pfizer rose by one notch from Aa2 to Aa1, while market signals were steady for the bond-implied and EDFTM- implied ratings. Despite a dip to a low point of Aa3 on April 29, Pfizer s CDS-implied rating returned to Aa1 on May 20, matching its April 20 level. The bond-implied rating ticked down one notch from Aa3 to A1 on May 19. It had moved from A1 to Aa3 for two brief periods over the last 30 days (April 23 to April 28 and May 1 to May 19) before settling at A1 again, and remaining unaltered on May 20. The EDFTM- implied rating was unwavering at Aaa for the last 30 days; indeed it has been Aaa since July 17, 2012....

  
Source:
Document ID
PBC_170958
Report Type
Market Signals Review
Format:
PDF Adobe Acrobat
Buy Now

Moody's Capital Markets Research—Moody's Analytics offers research, unique tools and best practices for measuring and managing risk through expertise and experience in credit analysis, economic research and financial risk management.

About the Author


Cite this Report

  
MLA:
Moody's Capital Markets Research. "Pfizer Inc.: Market Signals Diverge After AstraZenica Bid Rejected (Capital Markets Research)" May 20, 2014. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Moody-s-Capital-Markets-Research/Pfizer-Inc-Market-Signals-Diverge-After-AstraZenica-Bid-Rejected-Capital-Markets-Research-2141-1907>
  
APA:
Moody's Capital Markets Research. (2014). Pfizer Inc.: Market Signals Diverge After AstraZenica Bid Rejected (Capital Markets Research) May 20, 2014. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Moody-s-Capital-Markets-Research/Pfizer-Inc-Market-Signals-Diverge-After-AstraZenica-Bid-Rejected-Capital-Markets-Research-2141-1907>
  
US$ 200.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.